LAG-3-Next Generation Immunotherapy Competitive Landscape and Market Forecast 2035

 Breaking News
  • No posts were found

LAG-3-Next Generation Immunotherapy Competitive Landscape and Market Forecast 2035

August 07
20:30 2020
LAG-3-Next Generation Immunotherapy Competitive Landscape and Market Forecast 2035

DelveInsight Business Research LLP
DelveInsight’s ‘LAG-3-Next Generation Immunotherapy Competitive Landscape and Market Forecast 2035’ report delivers an in-depth understanding of the LAG-3 as well as the market trends of LAG-3-Next Generation Immunotherapy in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Cancer Immunotherapy involves antibodies to inhibit immune checkpoint molecules. Fighting cancer with immunotherapy has revolutionized treatment for some patients and therapies targeting the immune checkpoint molecules such as CTLA-4 and PD-1 in melanoma, renal cancer, Hodgkin’s diseases and lung cancer.
  • Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint receptor protein found on the cell surface of effector T cells and regulatory T cells (Tregs) and functions to control T cell response, activation, and growth.
  • T cells are a type of white blood cells that are a part of the immune system. Activation of cytotoxic T cells by antigens enables them to kill unhealthy or foreign cells. It binds MHCII molecules and modulates T-cell function than either CTLA-4 or PD-1.

LAG-3-Next Generation Immunotherapy Market

LAG-3-Next Generation Immunotherapy Market is expected to generate USD 3,421 Million by 2035.

LAG-3-Next Generation Immunotherapy Market Drivers-

  • The launch of potential upcoming therapies in the LAG-3 target during the forecast period (2022–2035).
  • Addition of personalized drug therapies with combinational therapies to enhance the efficacy
  • Increasing funding for R&D expense
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics

LAG-3-Next Generation Immunotherapy Pipeline

  1. MGD013: MacroGenics/Zai Lab
  2. MBG453: Novartis
  3. Relatlimab: Bristol-Myers Squibb/Ono Pharmaceuticals
  4. Eftilagimod Alpha (IMP321): Immutep
  5. LAG525: Novartis
  6. MK-4280: Merck
  7. REGN3767: Regeneron
  8. FS118: F-star Therapeutics
  9. XmAb22841: Xencor
  10. INCAGN2385: Incyte Biosciences/Agenus
  11. RO7247669: Roche
  12. TSR-033: GlaxoSmithKline
  13. IBI110: Innovent Biologics (Suzhou) Co. Ltd.

And many others

Request for sample pages


Scope of the report

• The report covers the descriptive overview of LAG-3-Next Generation Immunotherapy, explaining its pathophysiology, and current trends in the research.

• Additionally, an all-inclusive account of emerging therapies for LAG-3-Next Generation Immunotherapy is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.

• A detailed review of LAG-3-Next Generation Immunotherapy market; historical and forecasted is included in the report, covering drug outreach in the 7MM.

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the LAG-3-Next Generation Immunotherapy market.

Table of contents

1. Key Insights

2. Executive Summary

3. Competitive Intensity of LAG-3-Next Generation Immunotherapy

4. Market Competition of LAG-3-Next Generation Immunotherapy

5. Technological innovations in LAG-3-Next Generation Immunotherapy

6. Multivariate analysis of the key players in LAG-3-Next Generation Immunotherapy

7. LAG-3-Next Generation Immunotherapy Market Overview at a Glance

7.1. Market Share (%) Distribution of Next-Generation Immunotherapy in 2035

8. Pipeline Therapeutics Analysis (Active Products)

9. Overview: Next Generation Immunotherapy

9.1. Immune Checkpoint Inhibitors

9.2. LAG-3

10. Future Prospects and Challenges in LAG-3-Next Generation Immunotherapy

10.1. Current Clinical Challenges in Immunotherapies

10.2. Future direction of improving response rates of Immunotherapy

11. SWOT Analysis

12. Epidemiology and Forecasting Assumptions

13. Emerging Drugs

13.1. Target indications of LAG-3

13.2. MGD013: MacroGenics/Zai Lab

13.2.1. Drug Description

13.2.2. Other Developmental Activities

13.2.3. Clinical Development

13.2.4. Product Profile

13.3. MBG453: Novartis

13.3.1. Product Description

13.3.2. Other Developmental Activities

13.3.3. Clinical Development

13.3.4. Product Profile

13.4. Relatlimab: Bristol-Myers Squibb/Ono Pharmaceuticals

13.4.1. Product Description

13.4.2. Other Developmental Activities

13.4.3. Clinical Development

13.4.4. Product Profile

13.5. Eftilagimod Alpha (IMP321): Immutep

13.5.1. Drug Description

13.5.2. Clinical Development

13.5.3. Product Profile

13.6. LAG525: Novartis

13.6.1. Product Description

13.6.2. Other Developmental Activities

13.6.3. Clinical Development

13.6.4. Product Profile

13.7. MK-4280: Merck

13.7.1. Product Description

13.7.2. Other Developmental Activities

13.7.3. Clinical Development

13.7.4. Product Profile

13.8. REGN3767: Regeneron

13.8.1. Product Description

13.8.2. Other Developmental Activities

13.8.3. Clinical Development

13.8.4. Product Profile

13.9. FS118: F-star Therapeutics

13.9.1. Product Description

13.9.2. Other Developmental Activities

13.9.3. Clinical Development

13.9.4. Product Profile

13.10. XmAb22841: Xencor

13.10.1. Product Description

13.10.2. Other Developmental Activities

13.10.3. Clinical Development

13.10.4. Product Profile

13.11. INCAGN2385: Incyte Biosciences/Agenus

13.11.1.  Product Description

13.11.2.  Other Developmental Activities

13.11.3.  Clinical Development

13.11.4.  Product Profile

13.12. RO7247669: Roche

13.12.1.  Product Description

13.12.2.  Other Developmental Activities

13.12.3.  Clinical Development

13.12.4.  Product Profile

13.13. TSR-033: GlaxoSmithKline

13.13.1.  Product Description

13.13.2.  Other Developmental Activities

13.13.3.  Clinical Development

13.13.4.  Product Profile

13.14. IBI110: Innovent Biologics (Suzhou) Co. Ltd.

13.14.1.  Product Description

13.14.2.  Other Developmental Activities

13.14.3.  Clinical Development

13.14.4.  Product Profile

14. Assessment by Indication

15. Assessment by Route of Administration

16. Assessment by Stage and Indication

17. Assessment by stage and Route of Administration

18. LAG-3-7 Major Market Analysis

18.1. Market Outlook in the 7MM

18.1.1. Total Market size of LAG-3 in 7MM

18.1.2. Market Size of LAG-3 by indication in 7MM

19. Market Drivers

20. Market Barriers

21. Appendix

21.1. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight


Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States